References
- Lamm DL. Carcinoma in situ. Urol Clin North Am 1992; 19: 499–508.
- Wolf H, Melsen F, Pedersen SE, Nielsen KT. Natural history of carcinoma in situ of the urinary bladder. Scand J Urol Nephrol 1994; 157 (Suppl): 147–51.
- Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, Ti and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163: 1124–9.
- Jakse G, Hall R, Bono A, Holt1 W, Carpentier P. Spaander JP, et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group Phase II Protocol 30861. Eur Urol 2001; 40: 144–50.
- Van Gils-Gielen RJ, Witjes WP, Caris CT, Debruyne FM, Witjes JA, Oosterhof GO. Risk factors in carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Urology 1995; 45: 581–6.
- Ovesen H, Horn T, Steven K. Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response Scand J Urol Nephrol 38 and p53 nuclear accumulation. J Urol 1997; 157: 1655–9.
- Griffiths TRL, Charlton M, Neal DE, Powell PH. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol 2002; 67: 2408–12.
- Kaasinen E, Wijkstrom H, Malmstrom PU, Helisten S, Duchek M, Mestad O, et al. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study. Eur Urol 2003; 43: 637–45.
- Sylvester RJ, van der Meijden AP, Lamm DL. Infra-vesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 1964–70.
- Zlotta AR, van Vooren JP, Huygen K, Drowart A, Decock M, Pirson M, et al. What is the optimal regimen for BCG intravesical therapy? Are six weekly instilla-tions necessary. Eur Urol 2000; 37: 470–7.
- Merz VW, Marth D, Kraft R, Ackermann DK, Zingg EJ, Studer TIE. Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guerin for carcinoma in situ of the bladder. Br J Urol 1995; 75: 180–4.
- Fitzpatrick JM, West AB, Butler MR, Lane V, O'Flynn JD. Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol 1986; 135: 920–2.
- Lockyer CR, Sedgwick JE, Gillatt DA. Beware the BCG failures: a review of one institution's results. Eur Urol 2002; 42: 542–6.
- Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 2003; 169: 1706–8.
- Herr HW, Cookson MS, Soloway SM. Upper tract tumors in patients with primary bladder cancer followed for 15 years. J Urol 1996; 156: 1286–7.
- Miller EB, Eure GR, Schellhammer PF. Upper tract transitional cell carcinoma following treatment of superficial bladder cancer with BCG. Urology 1993; 42: 26–30.